Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001209191-19-022055
Filing Date
2019-04-01
Accepted
2019-04-01 17:53:12
Documents
2
Period of Report
2019-03-28

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 2246
2 POA DOCUMENT poa.txt EX-24.3_845104 3763
  Complete submission text file 0001209191-19-022055.txt   7425
Mailing Address 600 CALIFORNIA ST., 17TH FLOOR SAN FRANCISCO CA 94108
Business Address 600 CALIFORNIA ST., 17TH FLOOR SAN FRANCISCO CA 94108 415-638-6556
Audentes Therapeutics, Inc. (Issuer) CIK: 0001628738 (see all company filings)

EIN.: 461606174 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address C/O AUDENTES THERAPEUTICS, INC. 600 CALIFORNIA STREET, 17TH FLOOR SAN FRANCISCO CA 94108
Business Address
Meltz Mark A (Reporting) CIK: 0001771329 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-37833 | Film No.: 19722103